Associated Papers
Decoding Allosteric Effects of Missense Variations in Drug Metabolism: Afrocentric CYP3A4 Alleles Explored.
Mwaniki RM et al.
Journal of Molecular Biology, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
In-silico screening and analysis of missense SNPs in human CYP3A4/5 affecting drug-enzyme interactions of FDA-approved COVID-19 antiviral drugs.
Abdelazim AA et al.
Scientific Reports, 2025
Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2023
Effects of 27 CYP3A4 protein variants on saxagliptin metabolism in vitro.
Liu Q et al.
Fundamental & Clinical Pharmacology, 2022
Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.
Zhai Q et al.
Frontiers in Pharmacology, 2022
Mechanistic insights on nsSNPs on binding site of renin and cytochrome P450 proteins: A computational perceptual study for pharmacogenomics evaluation.
Loganathan L et al.
Journal of Cellular Biochemistry, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6β-Hydroxylation.
Kumondai M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2021
Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism.
Chen B et al.
Chemical Research in Toxicology, 2020
Polymorphism in Cytochrome P450 3A4 Is Ethnicity Related.
Guttman Y et al.
Frontiers in Genetics, 2019
Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro.
Zhou XY et al.
Frontiers in Pharmacology, 2019
Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China.
Jin T et al.
Bmc Genetics, 2016
Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China.
Jin T et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 2015
Genetic polymorphisms in very important pharmacogenomic (VIP) variants in the Tibetan population.
Jin TB et al.
Genetics and Molecular Research : Gmr, 2015
Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China.
Wang L et al.
Bmc Genetics, 2015
Functional gene variants of CYP3A4.
Werk AN et al.
Clinical Pharmacology and Therapeutics, 2014
Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.
Kohlrausch FB et al.
Molecular Biology Reports, 2014
Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes.
Lee JS et al.
The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2013
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy.
Wang D et al.
Journal of Personalized Medicine, 2012
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Analysis of pharmacogenetic traits in two distinct South African populations.
Ikediobi O et al.
Human Genomics, 2011
Evaluation of the effects of cytochrome P450 nonsynonymous single-nucleotide polymorphisms on tanshinol borneol ester metabolism and inhibition potential.
Liu D et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2010
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Lakhman SS et al.
Pharmacogenomics, 2009
A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450.
Wang LL et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants.
Peters EJ et al.
Pharmacogenomics, 2008
Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.
Lee SJ et al.
Journal of Clinical Pharmacology, 2006
The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH et al.
Journal of Human Genetics, 2006
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
Keshava C et al.
American Journal of Epidemiology, 2004
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.
Tsuchiya K et al.
Biochemical and Biophysical Research Communications, 2004
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms.
Ingelman-Sundberg M
Naunyn-schmiedeberg's Archives of Pharmacology, 2004
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
Lamba JK et al.
Pharmacogenetics, 2002
Identification and functional characterization of eight CYP3A4 protein variants.
Eiselt R et al.
Pharmacogenetics, 2001